Theriva Biologics, Inc. (TOVX) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the TerraEV Biologics Formally Synthetic Biologics 2022 Third Quarter Operational Highlights and Financial Results. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Chris Calabresi, LifeSci Advisors Relationship Manager. Please go ahead, sir. Thank you, Operator, and good morning, everyone. Welcome to the Theriva Biologics 2022 Third Quarter Investor Conference Call. Leading the call today will be Stephen Shawcross, Chief Executive and Chief Financial Officer of Theriva Biologics. Dr. Manel Cascaio, General Director of Theriva Biologics European Subsidiary, Dr. Frank Tafaro, Chief Operating Officer, and Dr. Vince Wacher, Head of Corporate and Product Development of Theriva Biologics are also on the call and will be available to answer questions during the Q&A session. Cereva Biologics issued a press release last evening which provided operational highlights and included the financial results for the third quarter ending September 30, 2022. The press release can be found in the investor section of the company website at www.cerevabio.com, together with the quarterly report on Form 10-Q for the quarter ended September 30, 2022. which we filed last night with the Securities and Exchange Commission. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website, www.CerevaBio.com, for 90 days. During this call, certain forward-looking statements regarding Cereva Biologics and DCN Biosciences, current expectations and projections about future events will be made. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions....